Co‐morbidity in the ageing haemophilia patient: the down side of increased life expectancy
Eveline P. Mauser‐Bunschoten(Utrecht University), Roger E. G. Schutgens(University Medical Center Utrecht), Dietje E. Fransen van de Putte(University Medical Center Utrecht)
Cited by 105
Related Papers
Bleeding in carriers of hemophilia
|Blood|2006|369
Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
|Blood|2017|300
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
|Haemophilia|2011|244
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
|The Lancet Haematology|2021|237